This research develops thiadiazole-based VEGFR-2 inhibitors, improving selectivity in cancer therapy, suggesting safer profiles.
Background Vascular endothelial growth factor receptor-2 (VEGFR-2) is a validated target in cancer therapy. However, approved inhibitors like sorafenib are often limited by off-target toxicity and resistance. This study aimed to develop novel thiadiazole-based VEGFR-2 inhibitors with improved selectivity and safer profiles.
No takes yet. Share an insight, caveat, or question.
Elkaeed et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: